These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24732772)

  • 1. Regulatory issues in cell-based therapy for clinical purposes.
    Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
    Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
    Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
    Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a cell-based medicinal product: regulatory structures in the European Union.
    Gálvez P; Clares B; Hmadcha A; Ruiz A; Soria B
    Br Med Bull; 2013; 105():85-105. PubMed ID: 23184855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
    Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
    Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quality risk management model approach for cell therapy manufacturing.
    Lopez F; Di Bartolo C; Piazza T; Passannanti A; Gerlach JC; Gridelli B; Triolo F
    Risk Anal; 2010 Dec; 30(12):1857-71. PubMed ID: 20723148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA issues guidance on regulation of cell-based products in animals.
    J Am Vet Med Assoc; 2014 Sep; 245(5):474. PubMed ID: 25289407
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Media fill for validation of a good manufacturing practice-compliant cell production process.
    Serra M; Roseti L; Bassi A
    Methods Mol Biol; 2015; 1283():161-9. PubMed ID: 25096172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory aspects for translating gene therapy research into the clinic.
    Laurencot CM; Ruppel S
    Methods Mol Biol; 2009; 542():397-421. PubMed ID: 19565915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
    McGowan NWA; Campbell JDM; Mountford JC
    Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development.
    Carmen J; Burger SR; McCaman M; Rowley JA
    Regen Med; 2012 Jan; 7(1):85-100. PubMed ID: 22168500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.